Phase III Trial Binimetinib Increases PFS in NRAS-Mutant Melanoma vs. Dacarbazine

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.

April 04, 2025

Vol.51 No.13

By Paul Goldberg

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).

April 04, 2025

Vol.51 No.13

By Claire Marie Porter, Paul Goldberg and Jacquelyn Cobb

Conversation with The Cancer Letter

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Brian J. Druker summits Mt. Hood in 1996The last time Brian J. Druker ran a marathon, his daughter, Julia, was six months old.

Rathmell: We must put the individual at the center of our approach to ending cancer

When I started this column, I was wanting to retain the sense of connection that I had to the greater cancer community as I stepped away into a period of disconnection.

April 04, 2025

Vol.51 No.13

By W. Kimryn Rathmell

How City of Hope is using AI to improve surgical outcomes

With recent leaps in artificial intelligence, there is major potential to turn computing advances into gains for human health.

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.

April 04, 2025

Vol.51 No.13

By Jacquelyn Cobb

Phase III Trial Binimetinib Increases PFS in NRAS-Mutant Melanoma vs. Dacarbazine

YOU MAY BE INTERESTED IN

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Rathmell: We must put the individual at the center of our approach to ending cancer

How City of Hope is using AI to improve surgical outcomes

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Renew today!

Subscriber content

Phase III Trial Binimetinib Increases PFS in NRAS-Mutant Melanoma vs. Dacarbazine

YOU MAY BE INTERESTED IN

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDAMeanwhile, NASEM sounds “SOS” for health infrastructure

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising recordCurrent record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Rathmell: We must put the individual at the center of our approach to ending cancer

How City of Hope is using AI to improve surgical outcomes

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed